Newsroom.

• Industry Leadership Award
• Company of the Year
• Emerging Company of the Year

The AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards were announced today at the AusBiotech 2018 national conference in Brisbane. The Awards recognise innovative companies and individuals in Australia’s world-class biotechnology, medical technology and healthcare sectors.

Ms Kathy Connell, Senior Director New Ventures, ANZ, Johnson & Johnson Innovation, said: “Johnson & Johnson Innovation is extremely proud to sponsor these awards and celebrate the passion and creativity of these extraordinary recipients as they advance biomedical research and healthcare innovation. Each of them is a true champion of science, working on mission-critical improvements to healthcare access, impact and outcomes for patients all around the world.”

AusBiotech’s Chief Executive Officer, Lorraine Chiroiu, said: “The annual Awards are an opportunity to recognise outstanding contributions to the sector, for which we are very grateful, as they demonstrate what is possible when vision and dedication come together.”

“These awards recognise the notable highlights of the abundant excellence in our industry and encourage us with what can be achieved when innovation is accompanied by the business acumen needed to bring new health technologies to patients.”

This year the Awards received an overwhelming number of emerging company nominations, demonstrating the positive Australian environment our life sciences companies are working within. For the first time ever, joint-winners are being awarded for this category.

Industry Leadership Award: Dr Anna Lavelle
Company of the Year: Medicines Development for Global Health
Joint Emerging Company of the Year: Telix Pharmaceuticals and Microba

- ENDS -

Media enquiries: Karen Parr, Communications Manager, AusBiotech

More about:

Industry Leadership Award: Dr Anna Lavelle
Dedicating her life to biotechnology, Dr Anna Lavelle has worked for over 25 years campaigning for the growth and expansion of the life sciences and medical technologies sector.

Anna holds a PhD in Genetics from the University of Melbourne and is a Graduate of the Australian Institute of Company Directors (GAICD). She is also a Fellow of the Academy of Technology Science and Engineering (FTSE) and a Fellow of the Leadership Victoria Program. 

Anna spent 11 years as AusBiotech’s CEO where she advocated for policy changes, including the R&D tax incentive. During this time, she became the only Australian to be recognised by Nature Scientific America as one of the world’s top 100 visionaries in biotechnology.

In addition to currently being the Independent Chair of Medicines Australia, Anna continues to serve the industry via a number of governance and advisory roles including: Non-executive Director Haemokinesis, Chair Australia National Digital Health initiative (ANDHealth), Independent Director CRC-HPS, Chairman Avatar Brokers and is Senior Advisor to MTPConnect.

Company of the Year: Medicines Development for Global Health
Medicines Development for Global Health are dedicated to developing affordable medicines and vaccines that may have limited commercial opportunity, but which address important unmet medical needs. Their sustained record of commitment and achievement in the biotechnology industry has recently culminated with US FDA registration approval for moxidectin to treat river blindness; an extraordinary accomplishment on many fronts.

Joint Emerging Company of the Year: Telix Pharmaceuticals and Microba
Telix Pharmaceuticals, established in November 2015, has demonstrated impressively rapid growth. Developing molecularly-targeted radiation (MTR) therapies, they’re killing cancer cells, shrinking tumours and halting disease growth. Telix Pharmaceuticals was ASX listed in November 2017 and raising more than $50 million, they represent the largest capital raised for a biotechnology company since CSL in 1997. They are expecting their first revenues before the end of this year. Fighting global health concerns, they are leveraging their international collaborations and relationships while fostering local talent, having created more than 20 new positions in 2018 alone.

Microba has developed the first at-home faecal test to identify species level resolution of gut microbiome. A spin-out from the University of Queensland, they have raised $7 million in Series A Capital, and, this year, launched their first product to market. Already supplying over 3,000 individuals with personal gut health information, they have raised over $1 million in revenue. Microba has also built research and development facilities (including a state of the art laboratory), a database of over 800 newly discovered species of microorganisms, filed three international patents, and has 40 research partnerships with Australian academics, clinicians, and other companies to advance gut microbiome research.